Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
2 other identifiers
interventional
1,146
4 countries
253
Brief Summary
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started May 2012
253 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2012
CompletedFirst Posted
Study publicly available on registry
March 14, 2012
CompletedStudy Start
First participant enrolled
May 29, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 9, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
January 9, 2014
CompletedResults Posted
Study results publicly available
July 30, 2018
CompletedJuly 30, 2018
July 1, 2018
1.6 years
March 8, 2012
June 11, 2018
July 27, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores
Composite responders were defined as participants who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score \<5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.
Up to 12 weeks
Secondary Outcomes (13)
Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores
Up to 26 weeks
Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals
12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)
Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals
12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)
Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals
12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)
Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale
Weeks 4, 8, 12, 18, 26 and 30 (End of Treatment [EOT])
- +8 more secondary outcomes
Study Arms (3)
Eluxadoline 75 mg
EXPERIMENTALEluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.
Eluxadoline 100 mg
EXPERIMENTALEluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.
Placebo
PLACEBO COMPARATOREluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.
Interventions
Oral tablets twice daily
Eligibility Criteria
You may qualify if:
- Participant is 18 to 80 years old
- Participant has a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea defined by the Rome III criteria.
- \. Participant has had a colonoscopy performed:
- Within 10 years prior to Prescreening if participant is at least 50 years of age (sigmoidoscopy, double contrast barium enema, or computed tomography (CT) colonography within the past 5 years is acceptable)
- Since the onset (if applicable) of any of the following alarm features for participants of any age
- Participant has documented weight loss within the past 6 months
- Participant has nocturnal symptoms
- Participant has a familial history of first-degree relatives with colon cancer
- Participant has blood mixed with their stool (excluding blood from hemorrhoids).
- \. Female participants must be:
- Postmenopausal, defined as 52 years or older and amenorrheic for at least 2 years at Prescreening,
- Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
- Abstinent, or
- If sexually active, be practicing an effective method of birth control.
You may not qualify if:
- Participant has a diagnosis of IBS with a subtype of constipation, mixed IBS, or unsubtyped IBS by the Rome III criteria.
- Participant has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis) and celiac disease.
- Participant has a history of diverticulitis within 3 months prior to Prescreening.
- Participant has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, or impaired intestinal circulation (eg, aortoiliac disease).
- Participant has any of the following surgical history:
- Cholecystectomy with any history of post cholecystectomy biliary tract pain
- Any abdominal surgery within the 3 months prior to Prescreening
- Participant has a history of major gastric, hepatic, pancreatic, or intestinal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post surgery are allowed)
- Other protocol-specific eligibility criteria may apply.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (253)
Furiex Research Site
Birmingham, Alabama, 35209, United States
Furiex Research Site
Birmingham, Alabama, 35242, United States
Furiex Research Site
Decatur, Alabama, 35603, United States
Furiex Research Site
Huntsville, Alabama, 35801, United States
Furiex Research Site
Mobile, Alabama, 36608, United States
Furiex Research Site
Montgomery, Alabama, 36109, United States
Furiex Research Site
Sheffield, Alabama, 35660, United States
Furiex Research Site
Tuscaloosa, Alabama, 35401, United States
Furiex Research Site
Glendale, Arizona, 85306, United States
Furiex Research Site
Glendale, Arizona, 85308, United States
Furiex Research Site
Mesa, Arizona, 85206, United States
Furiex Research Site
Phoenix, Arizona, 85023, United States
Furiex Research Site
Phoenix, Arizona, 85032, United States
Furiex Research Site
Tucson, Arizona, 85704, United States
Furiex Research Site
Tucson, Arizona, 85712, United States
Furiex Research Site
Jonesboro, Arkansas, 72401, United States
Furiex Research Site
Little Rock, Arkansas, 72205, United States
Furiex Research Site
Sherwood, Arkansas, 72120, United States
Furiex Research Site
Anaheim, California, 92801, United States
Furiex Research Site
Chula Vista, California, 91910, United States
Furiex Research Site
Encinitas, California, 92024, United States
Furiex Research Site
Garden Grove, California, 92840, United States
Furiex Research Site
Huntington Beach, California, 92647, United States
Furiex Research Site
Irvine, California, 92604, United States
Furiex Research Site
La Mesa, California, 91942, United States
Furiex Research Site
La Mirada, California, 90638, United States
Furiex Research Site
Laguna Hills, California, 92653, United States
Furiex Research Site
Lakewood, California, 90805, United States
Furiex Research Site
Lincoln, California, 95648, United States
Furiex Research Site
Loma Linda, California, 92354, United States
Furiex Research Site
Lomita, California, 90717, United States
Furiex Research Site
Long Beach, California, 90806, United States
Furiex Research Site
Los Angeles, California, 90045, United States
Furiex Research Site
Newport Beach, California, 92663, United States
Furiex Research Site
North Hollywood, California, 91606, United States
Furiex Research Site
Northridge, California, 91325, United States
Furiex Research Site
Pasadena, California, 91105, United States
Furiex Research Site
Sacramento, California, 95817, United States
Furiex Research Site
San Diego, California, 92103, United States
Furiex Research Site
San Diego, California, 92105, United States
Furiex Research Site
Santa Ana, California, 92701, United States
Furiex Research Site
Ventura, California, 93003, United States
Furiex Research Site
Walnut Creek, California, 94598, United States
Furiex Research Site
Denver, Colorado, 80211, United States
Furiex Research Site
Denver, Colorado, 80246, United States
Furiex Research Site
Boca Raton, Florida, 33428, United States
Furiex Research Site
Boynton Beach, Florida, 33426, United States
Furiex Research Site
Bradenton, Florida, 34208, United States
Furiex Research Site
Brooksville, Florida, 34601, United States
Furiex Research Site
Clearwater, Florida, 33759, United States
Furiex Research Site
Cooper City, Florida, 33024, United States
Furiex Research Site
Coral Springs, Florida, 33065, United States
Furiex Research Site
Eustis, Florida, 32726, United States
Furiex Research Site
Fort Lauderdale, Florida, 33308, United States
Furiex Research Site
Hallandale, Florida, 33009, United States
Furiex Research Site
Hialeah, Florida, 33016, United States
Furiex Research Site
Jacksonville, Florida, 32205, United States
Furiex Research Site
Jupiter, Florida, 33458, United States
Furiex Research Site
Lauderdale Lakes, Florida, 33319, United States
Furiex Research Site
Melbourne, Florida, 32901, United States
Furiex Research Site
Miami, Florida, 33015, United States
Furiex Research Site
Miami, Florida, 33125, United States
Furiex Research Site
Miami, Florida, 33126, United States
Furiex Research Site
Miami, Florida, 33133, United States
Furiex Research Site
Miami, Florida, 33135, United States
Furiex Research Site
Miami, Florida, 33144, United States
Furiex Research Site
Miami, Florida, 33155, United States
Furiex Research Site
Miami, Florida, 33183, United States
Furiex Research Site
Miramar, Florida, 33025, United States
Furiex Research Site
New Port Richey, Florida, 34652, United States
Furiex Research Site
Orlando, Florida, 32806, United States
Furiex Research Site
Plant City, Florida, 33563, United States
Furiex Research Site
Port Orange, Florida, 32127, United States
Furiex Research Site
South Miami, Florida, 33143, United States
Furiex Research Site
St. Petersburg, Florida, 33705, United States
Furiex Research Site
St. Petersburg, Florida, 33709, United States
Furiex Research Site
Tampa, Florida, 33607, United States
Furiex Research Site
Wellington, Florida, 33414, United States
Furiex Research Site
Winter Haven, Florida, 33880, United States
Furiex Research Site
Winter Park, Florida, 32792, United States
Furiex Research Site
Alpharetta, Georgia, 30005, United States
Furiex Research Site
Athens, Georgia, 30606, United States
Furiex Research Site
Atlanta, Georgia, 30308, United States
Furiex Research Site
Atlanta, Georgia, 30338, United States
Furiex Research Site
Dunwoody, Georgia, 30338, United States
Furiex Research Site
Lawrenceville, Georgia, 30046, United States
Furiex Research Site
Macon, Georgia, 31201, United States
Furiex Research Site
Marietta, Georgia, 30066, United States
Furiex Research Site
Norcross, Georgia, 30092, United States
Furiex Research Site
Savannah, Georgia, 31404, United States
Furiex Research Site
Stockbridge, Georgia, 30281, United States
Furiex Research Site
Boise, Idaho, 83704, United States
Furiex Research Site
Eagle, Idaho, 83616, United States
Furiex Research Site
Idaho Falls, Idaho, 83404, United States
Furiex Research Site
Addison, Illinois, 60101, United States
Furiex Research Site
Chicago, Illinois, 60612, United States
Furiex Research Site
Chicago, Illinois, 60622, United States
Furiex Research Site
Evergreen Park, Illinois, 60805, United States
Furiex Research Site
Hammond, Illinois, 46324, United States
Furiex Research Site
Springfield, Illinois, 62703, United States
Furiex Research Site
Brownsburg, Indiana, 46112, United States
Furiex Research Site
Evansville, Indiana, 47714, United States
Furiex Research Site
Granger, Indiana, 46530, United States
Furiex Research Site
Clive, Iowa, 50325, United States
Furiex Research Site
Pratt, Kansas, 67124, United States
Furiex Research Site
Shawnee Mission, Kansas, 66218, United States
Furiex Research Site
Topeka, Kansas, 66606, United States
Furiex Research Site
Lexington, Kentucky, 40503, United States
Furiex Research Site
Lexington, Kentucky, 40504, United States
Furiex Research Site
Owensboro, Kentucky, 42303, United States
Furiex Research Site
Paducah, Kentucky, 42003, United States
Furiex Research Site
Lake Charles, Louisiana, 70601, United States
Furiex Research Site
Monroe, Louisiana, 71201, United States
Furiex Research Site
Hagerstown, Maryland, 21742, United States
Furiex Research Site
Hollywood, Maryland, 20636, United States
Furiex Research Site
Boston, Massachusetts, 02115, United States
Furiex Research Site
Boston, Massachusetts, 02131, United States
Furiex Research Site
Brockton, Massachusetts, 02302, United States
Furiex Research Site
Watertown, Massachusetts, 02472, United States
Furiex Research Site
Ann Arbor, Michigan, 48106, United States
Furiex Research Site
Bay City, Michigan, 48706, United States
Furiex Research Site
Cadillac, Michigan, 49601, United States
Furiex Research Site
Grand Rapids, Michigan, 49506, United States
Furiex Research Site
Kalamazoo, Michigan, 49009, United States
Furiex Research Site
Troy, Michigan, 48098, United States
Furiex Research Site
Ypsilanti, Michigan, 48197, United States
Furiex Research Site
Plymouth, Minnesota, 55446, United States
Furiex Research Site
Biloxi, Mississippi, 39531, United States
Furiex Research Site
City of Saint Peters, Missouri, 63376, United States
Furiex Research Site
Hazelwood, Missouri, 63042, United States
Furiex Research Site
St Louis, Missouri, 63122, United States
Furiex Research Site
St Louis, Missouri, 63128, United States
Furiex Research Site
St Louis, Missouri, 63141, United States
Furiex Research Site
Billings, Montana, 59101, United States
Furiex Research Site
Bellevue, Nebraska, 68005, United States
Furiex Research Site
Elkhorn, Nebraska, 68022, United States
Furiex Research Site
Lincoln, Nebraska, 68510, United States
Furiex Research Site
Omaha, Nebraska, 68134, United States
Furiex Research Site
Omaha, Nebraska, 68144, United States
Furiex Research Site
Las Vegas, Nevada, 89123, United States
Furiex Research Site
Reno, Nevada, 89511, United States
Furiex Research Site
Lebanon, New Hampshire, 03756, United States
Furiex Research Site
Blackwood, New Jersey, 08012, United States
Furiex Research Site
Edison, New Jersey, 08817, United States
Furiex Research Site
Elizabeth, New Jersey, 07201, United States
Furiex Research Site
Marlton, New Jersey, 08053, United States
Furiex Research Site
Albuquerque, New Mexico, 87102, United States
Furiex Research Site
Albuquerque, New Mexico, 87108, United States
Furiex Research Site
Albuquerque, New Mexico, 87109, United States
Furiex Research Site
Flushing, New York, 11367, United States
Furiex Research Site
Hollis, New York, 11423, United States
Furiex Research Site
Mineola, New York, 11501, United States
Furiex Research Site
New York, New York, 10016, United States
Furiex Research Site
Chapel Hill, North Carolina, 27599, United States
Furiex Research Site
Dunn, North Carolina, 28334, United States
Furiex Research Site
Greensboro, North Carolina, 27403, United States
Furiex Research Site
Huntersville, North Carolina, 28078, United States
Furiex Research Site
Kinston, North Carolina, 28501, United States
Furiex Research Site
Wilmington, North Carolina, 28403, United States
Furiex Research Site
Winston-Salem, North Carolina, 27103, United States
Furiex Research Site
Winston-Salem, North Carolina, 27106, United States
Furiex Research Site
Akron, Ohio, 44302, United States
Furiex Research Site
Beavercreek, Ohio, 45431, United States
Furiex Research Site
Cincinnati, Ohio, 45224, United States
Furiex Research Site
Cincinnati, Ohio, 45242, United States
Furiex Research Site
Cincinnati, Ohio, 45245, United States
Furiex Research Site
Cincinnati, Ohio, 45267, United States
Furiex Research Site
Cleveland, Ohio, 44122, United States
Furiex Research Site
Columbus, Ohio, 43212, United States
Furiex Research Site
Columbus, Ohio, 43214, United States
Furiex Research Site
Columbus, Ohio, 43235, United States
Furiex Research Site
Dayton, Ohio, 45432, United States
Furiex Research Site
Dayton, Ohio, 45439, United States
Furiex Research Site
Groveport, Ohio, 43125, United States
Furiex Research Site
Kettering, Ohio, 45429, United States
Furiex Research Site
Lima, Ohio, 45806, United States
Furiex Research Site
Tiffin, Ohio, 44883, United States
Furiex Research Site
Toledo, Ohio, 43615, United States
Furiex Research Site
Norman, Oklahoma, 73071, United States
Furiex Research Site
Oklahoma City, Oklahoma, 73102, United States
Furiex Research Site
Oklahoma City, Oklahoma, 73112, United States
Furiex Research Site
Portland, Oregon, 97210, United States
Furiex Research Site
Salem, Oregon, 97301, United States
Furiex Research Site
Carnegie, Pennsylvania, 15106, United States
Furiex Research Site
Philadelphia, Pennsylvania, 19107, United States
Furiex Research Site
Pittsburgh, Pennsylvania, 15206, United States
Furiex Research Site
Pittsburgh, Pennsylvania, 15243, United States
Furiex Research Site
Scottdale, Pennsylvania, 15683, United States
Furiex Research Site
Uniontown, Pennsylvania, 15401, United States
Furiex Research Site
Warwick, Rhode Island, 02888, United States
Furiex Research Site
Anderson, South Carolina, 29621, United States
Furiex Research Site
Columbia, South Carolina, 29201, United States
Furiex Research Site
Columbia, South Carolina, 29203, United States
Furiex Research Site
Columbia, South Carolina, 29204, United States
Furiex Research Site
Easley, South Carolina, 29640, United States
Furiex Research Site
Mt. Pleasant, South Carolina, 29464, United States
Furiex Research Site
North Myrtle Beach, South Carolina, 29582, United States
Furiex Research Site
Rapid City, South Dakota, 57702, United States
Furiex Research Site
Athens, Tennessee, 37303, United States
Furiex Research Site
Chattanooga, Tennessee, 37404, United States
Furiex Research Site
Columbia, Tennessee, 38401, United States
Furiex Research Site
Jackson, Tennessee, 38305, United States
Furiex Research Site
Knoxville, Tennessee, 37919, United States
Furiex Research Site
Smyrna, Tennessee, 37167, United States
Furiex Research Site
Austin, Texas, 78745, United States
Furiex Research Site
Beaumont, Texas, 77701, United States
Furiex Research Site
Bedford, Texas, 76021, United States
Furiex Research Site
Corsicana, Texas, 75110, United States
Furiex Research Site
Dallas, Texas, 75218, United States
Furiex Research Site
Dallas, Texas, 75225, United States
Furiex Research Site
Fort Worth, Texas, 76133, United States
Furiex Research Site
Frisco, Texas, 75035, United States
Furiex Research Site
Houston, Texas, 77008, United States
Furiex Research Site
Houston, Texas, 77043, United States
Furiex Research Site
Houston, Texas, 77062, United States
Furiex Research Site
Humble, Texas, 77338, United States
Furiex Research Site
Hurst, Texas, 76054, United States
Furiex Research Site
San Antonio, Texas, 78215, United States
Furiex Research Site
San Antonio, Texas, 78229, United States
Furiex Research Site
San Antonio, Texas, 78258, United States
Furiex Research Site
Bountiful, Utah, 84010, United States
Furiex Research Site
Salt Lake City, Utah, 84124, United States
Furiex Research Site
West Valley City, Utah, 84120, United States
Furiex Research Site
Burlington, Vermont, 05401, United States
Furiex Research Site
Alexandria, Virginia, 22304, United States
Furiex Research Site
Christiansburg, Virginia, 24073, United States
Furiex Research Site
Midlothian, Virginia, 23114, United States
Furiex Research Site
Norfolk, Virginia, 23502, United States
Furiex Research Site
Richmond, Virginia, 23233, United States
Furiex Research Site
Richmond, Virginia, 23235, United States
Furiex Research Site
Charleston, West Virginia, 25304, United States
Furiex Research Site
Monroe, Wisconsin, 53566, United States
Furiex Research Site
Kelowna, British Columbia, V1Y 3G8, Canada
Furiex Research Site
St. John's, Newfoundland and Labrador, A1E 2E2, Canada
Furiex Research Site
Burlington, Ontario, L7M 4Y1, Canada
Furiex Research Site
Greater Sudbury, Ontario, P3E 1H5, Canada
Furiex Research Site
Hawkesbury, Ontario, K6A 1A1, Canada
Furiex Research Site
London, Ontario, N5W 6A2, Canada
Furiex Research Site
Newmarket, Ontario, L3Y 5G8, Canada
Furiex Research Site
Sarnia, Ontario, N7T 4X3, Canada
Furiex Research Site
Toronto, Ontario, M6H 3M1, Canada
Furiex Research Site
Vaughan, Ontario, L4L 4Y7, Canada
Furiex Research Site
San Juan, 00926-2832, Puerto Rico
Furiex Research Site
Chestfield, Kent, CT5 3QS, United Kingdom
Furiex Research Site
Blackpool, Lancashire, FY4 3AD, United Kingdom
Furiex Research Site
Birmingham, B15 2TH, United Kingdom
Furiex Research Site
County Durham, DL14 6AD, United Kingdom
Furiex Research Site
Coventry, CV2 2DX, United Kingdom
Furiex Research Site
Durham, DH1 5TW, United Kingdom
Furiex Research Site
Edinburgh, EH4 2XH, United Kingdom
Furiex Research Site
Manchester, M23 9LT, United Kingdom
Furiex Research Site
Sheffield, S10 2JF, United Kingdom
Furiex Research Site
Wigan, WN1 2NN, United Kingdom
Related Publications (2)
Fant RV, Henningfield JE, Cash BD, Dove LS, Covington PS. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3.
PMID: 28167156DERIVEDLembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, Covington PS. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med. 2016 Jan 21;374(3):242-53. doi: 10.1056/NEJMoa1505180.
PMID: 26789872DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Therapeutic Area Head
- Organization
- Allergan
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 8, 2012
First Posted
March 14, 2012
Study Start
May 29, 2012
Primary Completion
January 9, 2014
Study Completion
January 9, 2014
Last Updated
July 30, 2018
Results First Posted
July 30, 2018
Record last verified: 2018-07